“To further expand the current achievements in clinical cancer proteogenomic discoveries and infrastructure, NCI is soliciting applications for the reissuance of its Clinical Proteomic Tumor Analysis Consortium (CPTAC) program.”
“Three Funding Opportunity Announcements, the first being of particular interest to the data science community, are currently open to all qualified applicants, regardless of whether they participated in the previous issuance of the CPTAC program.”
“Proteogenomic Data Analysis Centers (PGDACs) for CPTAC (Clinical Trial Not Allowed)
Description: PGDAC awardees will be expected to develop computational tools for data analysis, data integration, and visualization and apply these tools to CPTAC data. The tools and approaches proposed for PGDACs should be suitable for analyses and meaningful interpretations of data derived from diverse types of samples (such as clinical specimens, cultured cells, and animal models of human cancers).
Letter of Intent Due Date: 30 days prior to application due date…” Read the full press release here.
Source: Proteomic Data Analysis Centers One of NCI’s Reissued Funding Opportunities: Apply by June 30 — April 14, 2021. National Cancer Institute.
